

SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Symdeko® (tezacaftor/ivacaftor)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

Recommended Dosing:

- Pediatric patients aged 6 to less than 12 years weighing less than 30 kg: one tablet (containing tezacaftor 50 mg/ivacaftor 75 mg) in the morning and one tablet (containing ivacaftor 75 mg) in the evening, approximately 12 hours apart. SYMDEKO should be taken with fat-containing food.
- Adults and pediatric patients aged 12 years and older or pediatric patients aged 6 to less than 12 years weighing 30 kg or more: one tablet (containing tezacaftor 100 mg/ivacaftor 150 mg) in the morning and one tablet (containing ivacaftor 150 mg) in the evening, approximately 12 hours apart. SYMDEKO should be taken with fat-containing food.

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 6 months

- ☐ Member is **6 years of age or older** with a diagnosis of Cystic Fibrosis

(Continued on next page)

- ☐ Member must have **ONE** of the following mutation types in the cystic fibrosis transmembrane conductance regulator (CFTR) gene:
 - ☐ Member is homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (**test result must be attached**)
 - ☐ Member has **at least one mutation** in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to Symdeko[®] detected by an FDA-cleared test (**test result must be attached**)
- ☐ Prescribing physician is a pulmonologist or has consulted with a pulmonologist who specializes in the treatment of Cystic Fibrosis
- ☐ Baseline FEV₁ within the last 30 days must be submitted (**test results must be attached**), unless the member is unable to perform a pulmonary function test (**documentation required**)
- ☐ Number of pulmonary exacerbations or hospitalizations in the preceding 6 months must be noted:

- ☐ Baseline body mass index must be noted: _____
- ☐ Baseline liver function tests have been completed prior to initiating therapy and will be completed annually (**labs must be attached**)
- ☐ Provider attests a baseline ophthalmic examination to monitor lens opacities/cataracts has been completed for pediatric members
- ☐ Member will **NOT** be taking Symdeko[®], in combination with any other CFTR modulator therapy (i.e., Orkambi[®], Kalydeco[®], Trikafta[™], Alyftrek[™]); **NOTE**: concurrent therapy with these agents will **NOT** be approved
- ☐ Member will avoid concomitant use of strong CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's Wort) and strong or moderate CYP3A inhibitors (i.e. fluconazole, itraconazole)

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ☐ Member continues to meet all initial authorization criteria
- ☐ Member has demonstrated disease response as indicated by **one or more** of the following (**must submit current labs and chart notes**):
 - ☐ Decreased pulmonary exacerbations or hospitalizations compared to pretreatment baseline
 - ☐ Stabilization of lung function as measured by FEV₁ within the last year compared to baseline
 - ☐ Improvement in quality of life, weight gain, or growth
- ☐ Member has **NOT** received a lung transplant
- ☐ Member has experienced an absence of unacceptable toxicity from therapy (i.e., elevated transaminases (ALT or AST), development of cataracts or lens opacities)

(Continued on next page)

Date of initiation of Symdeko [®] therapy: _____	Re-Authorization Date: _____
Baseline FEV ₁ (last FEV ₁ prior to starting Symdeko [®]): _____	Current FEV ₁ (FEV ₁ AFTER last dose of Symdeko [®]): _____
Baseline Weight: _____	Current weight: _____
Baseline BMI: _____	Current BMI: _____
Number of hospitalizations since last approval of Symdeko [®] must be noted _____	

Medication being provided by Specialty Pharmacy – Proprium Rx
--

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****